Empagliflozin after Acute Myocardial Infarction | NEJM |
|
SGLT2 inhibitors improve cardiovascular outcomes in high-risk patients with diabetes, chronic kidney disease, or heart failure, but their effects after acute myocardial infarction are unknown.
Research findings are summarized in a new Quick Take video. To see the full article, follow this link: https://nej.md/4cEb6EB #cardiology #clinicalmedicine #clinicaltrials #nejm |